ISOPP CAPhO 2025 Symposium: Preventing a CAT-astrophe: Evidence Update and Translating Risk-Directed Strategies into Practice for Cancer-Associated Thrombosis

Cancer-associated thrombosis (CAT) is a leading cause of morbidity and mortality, yet uptake of thromboprophylaxis remains suboptimal, especially in the ambulatory setting. This session will review recent evidence shaping the evolving guideline recommendations for CAT prevention, and examine risk assessment tools to identify patients who may benefit. Considerations for anticoagulation selection and real-world barriers to implementation will be explored, focusing on the pharmacist’s role in leading strategies to drive improved, risk-based thromboprophylaxis. We will also take a big picture view of current global practice patterns, highlighting the need for benchmarking. Expect practical takeaways and actionable insights to preventing CAT in oncology care.

Learning objectives

1. Interpret the current evidence – summarise recent key clinical trials and their impact on guidelines updates for the prevention of cancer-associated thrombosis (CAT)
2. Apply risk assessment models – discuss the utility and limitations of risk stratification tools to assess patients with cancer who may benefit from thromboprophylaxis
3. Compare anticoagulation options – evaluate the efficacy, safety, and practical considerations of different antithrombotics used for primary prophylaxis in patients with cancer
4. Address barriers to implementation – identify common real-world challenges to integrating risk-directed thromboprophylaxis in cancer care
5. Develop pharmacist-led interventions – propose strategies for pharmacists to enhance uptake of primary thromboprophylaxis via multidisciplinary collaboration